

IL6R

Human anti-IL-6 Receptor (Sarilumab) mAb

Catalog No.	CSB113A CSB113B	Quantity:	200 µg 1.0 mg
Alternate Names:	REGN88, SAR153191, Kevzara		
Description:	Sarilumab is a fully human anti-IL-6R monoclonal IgG1 antibody that binds to both membrane bound and soluble interleukin 6 (IL-6) receptor forms, thus blocking the cis- and trans-inflammatory signaling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe Rheumatoid Arthritis (RA) in combination with methotrexate 4. RA is a chronic inflammatory disease characterized by polyarthritis and its treatment has been challenged by the different response in every patient 3. Subcutaneous administration of Sarilumab has been shown to decrease acute-phase reactant levels and improve in clinical RA symptoms 2.		
Concentration:	1.0 mg/ml		
UniProt ID (target):	P08887		
Source:	CHO cell line		
Isotype:	Human IgG1 kappa		
INN:	Sarilumab		
Specificity:	Human soluble and membrane-bound IL-6R		
Biologic Activity:	Binds to IL-6 receptor, inhibits IL-6 mediated signaling		
Formulation:	PBS, pH 7.5		
Purity:	> 95% as determined by SDS-PAGE		
Reactivity:	Human		
Applications:	Functional studies, ELISA		
Storage & Stability:	Recommended storage, undiluted at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.